Zoetis Inc. (ZTS) Shares Sold by Gofen & Glossberg LLC IL
Gofen & Glossberg LLC IL lowered its position in Zoetis Inc. (NYSE:ZTS) by 1.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 297,915 shares of the company’s stock after selling 3,203 shares during the period. Gofen & Glossberg LLC IL owned 0.06% of Zoetis worth $15,495,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Ngam Advisors L.P. boosted its position in Zoetis by 88.0% in the second quarter. Ngam Advisors L.P. now owns 200,416 shares of the company’s stock worth $9,512,000 after buying an additional 93,838 shares during the last quarter. Cullen Frost Bankers Inc. boosted its position in Zoetis by 0.7% in the second quarter. Cullen Frost Bankers Inc. now owns 347,368 shares of the company’s stock worth $16,486,000 after buying an additional 2,470 shares during the last quarter. Columbus Circle Investors boosted its position in Zoetis by 43.9% in the second quarter. Columbus Circle Investors now owns 477,128 shares of the company’s stock worth $22,644,000 after buying an additional 145,641 shares during the last quarter. Raymond James Trust N.A. boosted its position in Zoetis by 5.0% in the second quarter. Raymond James Trust N.A. now owns 5,909 shares of the company’s stock worth $281,000 after buying an additional 281 shares during the last quarter. Finally, BARING ASSET MANAGEMENT Ltd boosted its position in Zoetis by 13.4% in the second quarter. BARING ASSET MANAGEMENT Ltd now owns 234,643 shares of the company’s stock worth $11,136,000 after buying an additional 27,812 shares during the last quarter. Institutional investors and hedge funds own 94.94% of the company’s stock.
Shares of Zoetis Inc. (NYSE:ZTS) traded up 0.22% on Monday, reaching $50.00. 2,730,212 shares of the company’s stock traded hands. The firm has a market cap of $24.69 billion, a P/E ratio of 36.05 and a beta of 1.05. The company’s 50-day moving average price is $50.32 and its 200 day moving average price is $49.55. Zoetis Inc. has a one year low of $38.26 and a one year high of $53.14.
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Wednesday, November 2nd. The company reported $0.52 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.46 by $0.06. Zoetis had a net margin of 14.10% and a return on equity of 72.96%. The firm earned $1.20 billion during the quarter, compared to analyst estimates of $1.22 billion. During the same quarter last year, the business posted $0.50 EPS. The company’s revenue for the quarter was up 2.2% on a year-over-year basis. On average, equities analysts forecast that Zoetis Inc. will post $1.94 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Thursday, November 3rd will be paid a dividend of $0.095 per share. The ex-dividend date of this dividend is Tuesday, November 1st. This represents a $0.38 annualized dividend and a dividend yield of 0.76%. Zoetis’s payout ratio is currently 27.54%.
ZTS has been the subject of a number of research analyst reports. Zacks Investment Research cut Zoetis from a “hold” rating to a “sell” rating in a report on Thursday, October 13th. Jefferies Group restated a “buy” rating and set a $60.00 price objective on shares of Zoetis in a report on Wednesday, September 14th. Bank of America Corp. assumed coverage on Zoetis in a report on Thursday, September 29th. They set a “buy” rating and a $60.00 price objective for the company. Guggenheim restated a “positive” rating and set a $60.00 price objective on shares of Zoetis in a report on Monday, August 22nd. Finally, JPMorgan Chase & Co. restated a “hold” rating and set a $53.00 price objective on shares of Zoetis in a report on Thursday, November 3rd. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $55.83.
In other news, insider Heidi C. Chen sold 32,097 shares of the firm’s stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $50.98, for a total transaction of $1,636,305.06. Following the completion of the sale, the insider now owns 46,060 shares in the company, valued at approximately $2,348,138.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Andrew Fenton sold 13,870 shares of the firm’s stock in a transaction that occurred on Friday, September 2nd. The stock was sold at an average price of $51.25, for a total transaction of $710,837.50. Following the sale, the insider now owns 17,719 shares of the company’s stock, valued at approximately $908,098.75. The disclosure for this sale can be found here. Insiders own 0.05% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.